TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00053417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 15 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
Description: 2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg fampridine-SR (4-aminopyridine, 4-AP)
Description: 10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Description: 2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)
Study: NCT04472585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Injectable Solution
Description: Subcutaneous Ivermectin 200ug/kg body weight 48 hourly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin Injectable Solution
Description: Subcutaneous Ivermectin 200ug/kg body weight 48 hourly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Placebo
Description: 0.9% normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc Sulphate 20mg 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc Sulphate 20mg 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc Sulphate 20mg 3 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo empty capsule
Description: Placebo empty capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ivermectin
Description: 0.2mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ivermectin
Description: 0.2mg/kg/day
Study: NCT03719274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c depigementation
Description: locally injected vitamin c depigementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c depigementation
Description: locally injected vitamin c depigementation
Study: NCT03673774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac impedancemetry
Description: The cardiac output is measured by impedance measurement at rest and during the walking test.
Study: NCT02389803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula
Description: Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Low caloric formula (Powder added to water), without added vitamins and minerals
Study: NCT01821651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartNavigator
Description: Procedure with software

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchoNav
Description: Procedure with software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-Group EN
Description: Procedure without software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-group HN
Description: Procedure without software
Study: NCT03901079

Intervention type: OTHER
Intervention: single-arm study
Description: single-arm study
Study: NCT03891173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOS47
Description: L-DOS47 lyophilized powder reconstituted and diluted for iv injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin concentrate for solution for iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin concentrate for solution for iv infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine concentrate for solution for iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine concentrate for solution for iv infusion
Study: NCT00718276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25(OH)D
Description: daily (20ug), weekly (140 ug), Bolus (140 ug)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
Study: NCT00855985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: type of anastomosis after pancreaticoduodenectomy
Description: pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: type of anastomosis after pancreaticoduodenectomy
Description: pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
Study: NCT03622489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramal
Description: mentioned above
Study: NCT03408392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation A
Description: Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation A
Description: Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference formulation B
Description: Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference formulation B
Description: Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
Study: NCT04843007

Intervention type: DRUG
Intervention: Pemetrexed
Description: Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2
Study: NCT01465555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
Study: NCT02120898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Cream, generic formulation of the brand product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyclara®
Description: Cream, brand product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.
Study: NCT01465919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive psychotherapy
Description: Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
Study: NCT02633150

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supplementation with red grapes polyphenol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplementation with red grapes polyphenol
Study: NCT01477398

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QED-100
Description: Use of the QED-100 results in mild hypercapnia during emergence
Study: NCT03820648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis
Description: The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 3M™ Steri-Drape 2
Description: Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
Study: NCT02371447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPM1002BC
Description: Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)
Study: NCT00634309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03724188

Intervention type: PROCEDURE
Intervention: surgical parathyroidectomy
Description: total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
Study: NCT02424032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and connective tissue massage
Description: Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
Study: NCT04558411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT) Skills
Description: 14 brief videos that teach DBT skills.
Study: NCT04283136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Padsevonil type 1 Tablet 200 mg
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period.
Study: NCT02808117

Intervention type: DIETARY_SUPPLEMENT
Intervention: MNP
Description: Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency.

Intervention type: DIETARY_SUPPLEMENT
Intervention: MNP
Description: Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency.
Study: NCT00724698

Intervention type: DRUG
Intervention: Desloratadine
Description: Desloratadine 5 mg once daily
Study: NCT05871216

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tests and balance evaluation using the Delos Proprioceptive System
Description: Each patient is evaluated using clinical tests (Time up and go test, 6 minutes walking test), scales (BORG scale, Beighton score), and the ''Delos Proprioceptive System'' to assess balance control and proprioception with bipodalic and monopodalic tests.
Study: NCT04048356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Description: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Description: Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Study: NCT04475796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy performed after ERCP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy performed after ERCP
Study: NCT01875796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivation Enhancement Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cannabis and Anxiety Reduction Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: False Safety Behavior Elimination Therapy
Study: NCT00784914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Receive temsirolimus IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cytokine levels
Description: Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytokine levels
Description: Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
Study: NCT03483402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse laser trabeculoplasty
Description: Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
Study: NCT03597945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine with epinephrine
Description: lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine with epinephrine
Description: lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
Study: NCT04283136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Padsevonil type 1 Tablet 200 mg
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Padsevonil type 1 Tablet 200 mg
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Padsevonil type 1 Tablet 200 mg
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Padsevonil type 1 Tablet 200 mg
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 2 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 3 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 4 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil type 5 Tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period.
Study: NCT00607386

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Idursulfase
Description: Solution for intravenous infusion, 0.5 mg/kg weekly
Study: NCT04572984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBMCB
Description: endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
Study: NCT02670863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant Formula
Description: Standard bovine milk-based term infant formula, fed ad libitum
Study: NCT00061542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BETOPTIC S (betaxolol HCl)
Description: betaxolol HC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Gel-forming Solution (TGFS)
Description: timolol maleate 0.25% and 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Gel-forming Solution (TGFS)
Description: timolol maleate 0.25% and 0.5%
Study: NCT01306448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant capsule
Description: vibrating capsule
Study: NCT01336582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxotere
Description: 70 mg/m2 for age of ≥ 65

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxotere
Description: 70 mg/m2 for age of ≥ 65
Study: NCT01108146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1 Hydrocortisone 10 mg
Description: Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2 Hydrocortisone 30 mg
Description: Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo
Study: NCT03119714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemirolast
Description: Treatment with pemirolast 200 mg bid for 14-16 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Treatment with placebo bid for 14-16 days
Study: NCT01827670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: Test dentifrice containing 0.454% SnF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate \[1000 parts per million (ppm) fluoride\]
Study: NCT01142401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies